Trial Profile
A multicenter, retrospective study to evaluate brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Feb 2020
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 01 Feb 2020 Results published in the Annals of Hematology
- 19 Nov 2015 New trial record